Physician profile
Laura E Holzer
NPI 1972862092
$1,452.51
in general payments reported to CMS, 2019-2025
32 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $356 · 2021: $192 · 2022: $91.23 · 2023: $18.18 · 2024: $83.75 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $159.28 | 2019-2022 | |
| Novo Nordisk INC | $132.07 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $129.44 | 2019-2022 | |
| Pfizer INC. | $109.87 | 2019-2020 | |
| Glaxosmithkline, LLC. | $107.37 | 2019-2022 | |
| Lilly USA, LLC | $91.72 | 2019-2021 | |
| Viatris Specialty LLC | $58.25 | 2025 | Yupelri |
| Eisai INC. | $55.12 | 2020-2025 | |
| Antares Pharma, INC. | $53.72 | 2019-2022 | |
| Edwards Lifesciences Corporation | $45.84 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $43.02 | 2019-2025 | Capvaxive |
| Exact Sciences Corporation | $42.99 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $38.35 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.89 | 2019-2020 | |
| Seqirus USA INC | $29.87 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $29.42 | 2021 | |
| Mylan Specialty L.P. | $24.56 | 2021 | |
| Abbott Laboratories | $23.43 | 2024 | Freestyle Libre 3 |
| Allergan, INC. | $23.31 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $22.13 | 2021 | |
| Shire North American Group INC | $21.88 | 2019 | |
| Biogen, INC. | $21.49 | 2025 | Leqembi |
| Amgen INC. | $20.43 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.18 | 2023 | |
| Evoke Pharma, INC. | $17.85 | 2024 | |
| Esperion Therapeutics, INC. | $17.65 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $15.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.65 | 2020 | |
| Horizon Therapeutics Plc | $14.47 | 2020 | |
| Amarin Pharma, INC. | $13.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.88 | 2021 | |
| Tactile Systems Technology INC | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Holzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.